A Study on the Safety and Efficacy of Adenosylcobalamin in Patients With Declining Ovarian Function
The goal of this clinical trial is to learn if adenosylcobalamin works to treat POI and DOR. It will also learn about the safety of adenosylcobalamin. The main questions it aims to answer are:
Can adenosylcobalamin improve the clinical symptoms, signs, and hormone levels of patients with POI and DOR? What is the safety of adenosylcobalamin?
Participants will:
Take adenosylcobalamin three times a day for 3 months Visit the clinic for 5 checkups and tests
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 4
連絡先と場所
研究連絡先
研究連絡先
- 名前:Liru Xue
- 電話番号:CN 18727297670
- メール:751400767@qq.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Premature Ovarian Insufficiency (POI): Age < 40 years old, with two consecutive basal FSH levels ≥ 25 U/L spaced 4 weeks apart, decreased anti-müllerian hormone (AMH), and clinical manifestations of oligomenorrhea or amenorrhea.
(2) Diminished ovarian reserve (DOR): Age < 40 years old, with a decrease in the number and/or quality of oocytes in the ovary, and/or accompanied by a decreased AMH level (< 1.1 ng/mL), and/or a reduced number of antral follicles (AFC) (< 6) and/or an elevated basal FSH level (> 10 U/L).
Exclusion Criteria:
- Abnormal uterine bleeding of unknown cause;
- Presence of ovarian/appendage masses ≥ 4 cm, uterine adenomyosis, uterine adenomyoma/uterine fibroids ≥ 4 cm;
- BI-RADS rating of breast ultrasound ≥ 4;
- Presence of precancerous lesions or having malignant tumors;
- Liver and kidney function indicators (ALT, AST, Urea, Cr) exceed the upper limit of normal reference values and have not returned to normal after re-examination;
- Complicated with severe primary diseases in the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems, or patients with mental disorders;
- Have received systemic hormone replacement therapy within the last 2 months;
- Are participating in other clinical trials or have participated in other clinical trials within the last 1 month;
- Have a recent fertility requirement;
- Other patients deemed unsuitable for participation in this study by the researchers.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:POI and DOR
|
Take oral adenosylcobalamin tablets, 0.5mg per dose, three times a day. Continue the treatment for 12 weeks. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
anti-müllerianhormone
時間枠:Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The serum anti-müllerianhormone(AMH) level is the primary indicator for evaluating ovarian reserve function and is used for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
|
sex hormones
時間枠:Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The sex hormone tests include estradiol, follicle-stimulating hormone(FSH), luteinizing hormone(LH), progesterone, testosterone and prolactin. Among them, FSH is the main indicator for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
|
antral follicles
時間枠:Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The number of antral follicles refers to the total count of antral follicles observed bilaterally in the ovaries through transvaginal ultrasound examination during the early stage of follicular development. Studies have confirmed that the number of antral follicles is related to the size of the primordial follicle pool, and it can be used to assess ovarian reserve function. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- TJ-IRB202611089
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。